Daniel P. Petrylak, MD, of Yale Cancer Center, discusses phase III study findings on docetaxel with or without ramucirumab in platinum-refractory advanced or metastatic urothelial carcinoma.
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program